Protection from cerebral ischemia by inhibition of TGFβ-activated kinase

Experimental Neurology

Volumn 237, Issue 1, 2012, Pages 238-245

  White, Benjamin J ^a   Tarabishy, Sami ^b   Venna, Venugopal Reddy ^b   Manwani, Bharti ^b   Benashski, Sharon ^b   McCullough, Louise D ^b   Li, Jun ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

AMPK; JNK; Stroke; TAK1

Indexed keywords

7 OXOZEAENOL; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVATION; GENE DELETION; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; PROTEIN KINASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; ZEARALENONE;

EID: 84864057949     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.05.019     Document Type: Article

References (43)

1. Benakis C., Bonny C., Hirt L. JNK inhibition and inflammation after cerebral ischemia. Brain Behav. Immun. 2010, 24:800-811.
2. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat. Protoc. 2006, 1:1306-1311.
3. Broglie P., Matsumoto K., Akira S., Brautigan D.L., Ninomiya-Tsuji J. Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway. J. Biol. Chem. 2010, 285:2333-2339.
4. Candelario-Jalil E., Fiebich B.L. Cyclooxygenase inhibition in ischemic brain injury. Curr. Pharm. Des. 2008, 14:1401-1418.
5. Dhawan J., Benveniste H., Luo Z., Nawrocky M., Smith S.D., Biegon A. A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol. 2011, 6:823-834.
6. 2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 1995, 270:27186-27191.
7. Iadecola C., Ross M.E. Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann. N. Y. Acad. Sci. 1997, 835:203-217.
8. Jang S.B., Won J., Kim H., Kim J., Lee K.H., Han H., Rha H.K., Choi C.R. TAK1 mediates lipopolysaccharide-induced RANTES promoter activation in BV-2 microglial cells. Mol. Cells 2002, 14:35-42.
9. Kajino T., Ren H., Iemura S., Natsume T., Stefansson B., Brautigan D.L., Matsumoto K., Ninomiya-Tsuji J. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006, 281:39891-39896.
10. Kilic E., Dietz G.P., Hermann D.M., Bahr M. Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann. Neurol. 2002, 52:617-622.
11. Kim S.I., Kwak J.H., Wang L., Choi M.E. Protein phosphatase 2A is a negative regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial cells. J. Biol. Chem. 2008, 283:10753-10763.
12. Kumar M., Makonchuk D.Y., Li H., Mittal A., Kumar A. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J. Immunol. 2009, 182:2439-2448.
13. Li J., McCullough L.D. Effects of AMP-activated protein kinase in cerebral ischemia. J. Cereb. Blood Flow Metab. 2010, 30:480-492.
14. Li J., Zeng Z., Viollet B., Ronnett G.V., McCullough L.D. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke 2007, 38:2992-2999.
15. Li J., Benashski S.E., Siegel C., Liu F., McCullough L.D. Adenosine monophosphate activated protein kinase inhibition is protective in both sexes after experimental stroke. Neurosci. Lett. 2010, 482:62-65.
16. Li J., Benashski S.E., Venna V.R., McCullough L.D. Effects of metformin in experimental stroke. Stroke 2010, 41:2645-2652.
17. Manwani B., Liu F., Xu Y., Persky R., Li J., McCullough L.D. Functional recovery in aging mice after experimental stroke. Brain Behav. Immun. 2011, 25:1689-1700.
18. Matluk N., Rochira J.A., Karaczyn A., Adams T., Verdi J.M. A role for NRAGE in NF-kappaB activation through the non-canonical BMP pathway. BMC Biol. 2010, 8:7.
19. Momcilovic M., Hong S.P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 2006, 281:25336-25343.
20. Neubert M., Ridder D.A., Bargiotas P., Akira S., Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011, 18:1521-1530.
21. Nijboer C.H., Heijnen C.J., Groenendaal F., van Bel F., Kavelaars A. Alternate pathways preserve tumor necrosis factor-alpha production after nuclear factor-kappaB inhibition in neonatal cerebral hypoxia-ischemia. Stroke 2009, 40:3362-3368.
22. Nijboer C.H., van der Kooij M.A., van Bel F., Ohl F., Heijnen C.J., Kavelaars A. Inhibition of the JNK/AP-1 pathway reduces neuronal death and improves behavioral outcome after neonatal hypoxic-ischemic brain injury. Brain Behav. Immun. 2010, 24:812-821.
23. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
24. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M., Mihara M., Tsuchiya M., Matsumoto K. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 2003, 278:18485-18490.
25. Omori E., Morioka S., Matsumoto K., Ninomiya-Tsuji J. TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J. Biol. Chem. 2008, 283:26161-26168.
26. Resch U., Schichl Y.M., Winsauer G., Gudi R., Prasad K., de Martin R. Siva1 is a XIAP-interacting protein that balances NFkappaB and JNK signalling to promote apoptosis. J. Cell Sci. 2009, 122:2651-2661.
27. Sakamoto K., McCarthy A., Smith D., Green K.A., Grahame Hardie D., Ashworth A., Alessi D.R. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 2005, 24:1810-1820.
28. Sakurai H., Miyoshi H., Mizukami J., Sugita T. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett. 2000, 474:141-145.
29. Sakurai H., Suzuki S., Kawasaki N., Nakano H., Okazaki T., Chino A., Doi T., Saiki I. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J. Biol. Chem. 2003, 278:36916-36923.
30. Sanna M.G., da Silva Correia J., Ducrey O., Lee J., Nomoto K., Schrantz N., Deveraux Q.L., Ulevitch R.J. IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell. Biol. 2002, 22:1754-1766.
31. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Matsumoto K., Takeuchi O., Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005, 6:1087-1095.
32. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., Irie K., Nishida E., Matsumoto K. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996, 272:1179-1182.
33. Sicard P., Jacquet S., Kobayashi K.S., Flavell R.A., Marber M.S. Pharmacological postconditioning effect of muramyl dipeptide is mediated through RIP2 and TAK1. Cardiovasc. Res. 2009, 83:277-284.
34. Sims N.R., Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim. Biophys. Acta 2010, 1802:80-91.
35. Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V., Schuster N., Zhang S., Heldin C.H., Landstrom M. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 2008, 10:1199-1207.
36. Suter M., Riek U., Tuerk R., Schlattner U., Wallimann T., Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 2006, 281:32207-32216.
37. Tang M., Wei X., Guo Y., Breslin P., Zhang S., Wei W., Xia Z., Diaz M., Akira S., Zhang J. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 2008, 205:1611-1619.
38. Thiefes A., Wolter S., Mushinski J.F., Hoffmann E., Dittrich-Breiholz O., Graue N., Dorrie A., Schneider H., Wirth D., Luckow B., Resch K., Kracht M. Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. J. Biol. Chem. 2005, 280:27728-27741.
39. Tuttolomondo A., Di Sciacca R., Di Raimondo D., Renda C., Pinto A., Licata G. Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr. Top. Med. Chem. 2009, 9:1240-1260.
40. Weisova P., Davila D., Tuffy L.P., Ward M.W., Concannon C.G., Prehn J.H. Role of 5'-adenosine monophosphate-activated protein kinase in cell survival and death responses in neurons. Antioxid. Redox Signal. 2011, 14:1863-1876.
41. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E., Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
42. Zeng K.W., Fu H., Liu G.X., Wang X.M. Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways. Int. Immunopharmacol. 2010, 10:668-678.
43. Zhang J., Lei T., Chen X., Peng Y., Long H., Zhou L., Huang J., Chen Z., Long Q., Yang Z. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation 2010, 33:25-33.